Answers are grounded in this paper and cite their sources.
Background Reliable venous access is a prerequisite for delivering systemic anticancer therapy. The advantage of the totally implantable venous access port (chemoport) over the peripherally inserted central catheter (PICC) for long-term treatment of solid tumours is now well established, most notably by the CAVA randomised trial. Less attention has been paid to where the alternatives fit, namely the tunnelled cuffed (Hickman-type) catheter, the midline catheter and the short peripheral cannula, and to how device choice changes when patients bear the cost and interventional radiology is scarce. This narrative review addresses those questions. Main body PubMed/MEDLINE, PubMed Central and major professional-society guidelines were searched for reports on complications, cost, quality of life and insertion technique (search last updated October 2026). Chemoports carry the lowest infection and thrombosis rates per catheter-day and are preferred by patients, but need a minor implantation procedure. PICCs can be placed at the bedside without a chest-wall incision but have a higher thrombosis risk and more frequent mechanical failure. Hickman-type catheters remain useful when multi-lumen, high-flow access is needed, particularly in haematological malignancy, but are more prone to infection than ports. Midline catheters and peripheral cannulas are appropriate only for short, non-vesicant regimens. Economic evaluations from the United Kingdom, Sweden and China generally favour ports for courses longer than about six months, whereas an Indian study and a Chinese colorectal cohort found substantially higher costs with ports, so cost conclusions do not transfer automatically between health systems. Consensus frameworks, including the Michigan Appropriateness Guide for Intravenous Catheters and a recent Indian expert consensus, offer structured selection algorithms, and experience from Nepal and India shows that surgeon-performed, ultrasound-guided port insertion is safe without dedicated interventional radiology. Conclusion Device selection should be individualised according to the vesicant potential and expected duration of the regimen, the patient's veins and thrombotic risk, and local resources and payment arrangements. A multidisciplinary vascular access pathway, including surgeon-led ultrasound-guided port insertion where interventional radiology is limited, can improve safety and treatment continuity for patients receiving chemotherapy.
No takes yet. Share an insight, caveat, or question.
Hirachan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: